SUBSCRIBE: Print / eNewsletter
Using Patient Variables in CML to Guide Treatment
This video highlights patient variables, including kidney function or history of diabetes, that can help guide treatment in chronic myeloid leukemia.
Latest Immunotherapy Approaches in Multiple Myeloma
This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma.
Maintenance Therapy in Mantle Cell Lymphoma
This video reviews different strategies for maintenance therapy in mantle cell lymphoma, as well as highlighting upcoming research in this setting.
Updates in the Treatment of Secondary Acute Myeloid Leukemia
This video reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease.
Treating Older Patients With Myeloma: Is Frailty More Important Than Age?
In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.
Targeting IDH in Acute Myeloid Leukemia
This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.
POLLUX/CASTOR: Daratumumab Improved Myeloma Outcomes Regardless of Risk Group
This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.
CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.